Maria Mendoza headshot

Maria A Mendoza

Clinical Assistant Professor
Program Director, Nursing Education

1 212 998 9002

433 1st Ave
New York, NY 10010
United States

expand all

collapse all

Professional overview

Maria A. Mendoza is the director of the nursing education program and a clinical assistant professor at the NYU Rory Meyers College of Nursing. As an experienced clinician and educator who specializes in curriculum design/evaluation and program development. She is a consultant to NYC Health + Hospital/Lincoln Medical Center in designing and evaluating a train-the-trainer program to enhance RN skills in patient-centered medical home and in developing and teaching the leadership skills for nurse managers. Her global collaboration with the faculty at Hue University of Medicine and Pharmacy in Vietnam includes consultation in developing a graduate nursing curriculum, faculty development on clinical teaching, and evidence-based practice. Mendoza is also part of the NYU Meyers & Health Resource & Service Administration "Resilient and Responsive Health System Initiative" project that successfully revised the Liberia pre-service RN curriculum in collaboration with the Liberian Board of Nursing and Midwifery. Mendoza also authors articles and chapters in diabetes self-management and nursing education. She is a reviewer for professional nursing journals, such as Clinical Nursing Research and Frontiers Public Health Education and Promotion.

Prior to joining the faculty at NYU, Mendoza served as director of nursing education at Brookdale University Hospital, where she expanded the continuing education program and implemented competency-based professional development education. She also practiced as an adult/gerontological nurse practitioner in primary care and diabetes at Jacobi Medical Center and North Central Bronx Hospital for 20 years. While there, she directed the Chronic Disease Management and Diabetes Education programs and coordinated the NIH landmark diabetes study "Action to Control Cardiovascular Risk in Diabetes (ACCORD)," and was co-primary investigator in other pharmaceutical research. As director of chronic disease management, she managed a population of over 5,000 patients with diabetes in the North Bronx Healthcare Network (NBHN) registry. Under her leadership, NBHN became the hospital with the best HbA1c outcomes in diabetes care among all the HHC hospital and community services. 

Mendoza received her DEd and MEd, as well as an MA in teaching, from Columbia University and a BA in nursing from Trinity College of Quezon City.


DEd - Columbia University
MEd, Adult Health - Columbia University
Gerontological Nurse Practitioner Certificate - New York Hospital/Cornell
MA, Teaching - Columbia University
BA, Nursing - Trinity College of Quezon City


Primary care
Adult health
Chronic disease
Palliative care

Professional membership

American Nurses Association - New York
National League for Nursing
New York Academy of Medicine
Philippine Nurses Association of America
Sigma Theta Tau

Honors and awards

Faculty Honors Awards

Corporate Nurse of the Year, New York Health (2010)
Fellow, New York Academy of Medicine



Social jetlag, circadian disruption, and cardiometabolic disease risk

Malone, S. K., Mendoza, M. A., & Patterson, F. (2019). In Sleep and Health (pp. 227-240). Elsevier. 10.1016/B978-0-12-815373-4.00018-6
The sun rises and sets over the earth in a predictable pattern. This pattern has existed for billions of years and has influenced the behavior of all living things. Behavioral rhythms have aligned with these light-dark rhythms and conferred an evolutionary advantage. Humans have adapted to the light-dark cycle so that activity occurs during the day and rest occurs during the night. Increased visibility afforded by daylight optimizes foraging and safety while being active. Reduced visibility during the night optimizes sleeping and fasting. Daily rhythms, such as light-dark, are known as circadian rhythms from the Latin words “circa,” for about, and “dias,” for a day. Physiological processes rely on predictable circadian rhythms. These processes include sleeping and waking, cardiac function, such as heart rate and blood pressure, and metabolic processes, such as glucose, lipid, and energy metabolism. Disrupting circadian rhythms can profoundly impact cardiometabolic health and well-being. Poor cardiometabolic health can also disrupt the circadian system. This chapter will briefly introduce the cardiometabolic syndrome, the circadian system, circadian disruption, and social jetlag as a form of circadian disruption.

Promoting synergistic partnerships in low resource countries: a case study exemplar

Upvall, M. J., Trang, H. T. T., Derstine, J. B., Mendoza, M. A., Sagar, P. L., & Scheans, P. (2017). Contemporary Nurse, 53(5), 589-595. 10.1080/10376178.2017.1388747
Objectives/Aims: The purpose of this discussion is to explore the dynamics of partnership and its impact on both nursing faculty at Hue University of Medicine and Pharmacy (HueUMP) and Health Volunteers Overseas (HVO) volunteers. Design: A case study approach was used to promote understanding of partnerships in global health. Discussion: Collaboration between HueUMP’s nursing program and HVO is one of the most dynamic HVO nurse educator programs with five volunteer visits to Vietnam within a two-year period. Volunteer efforts include workshops to meet the diverse needs and interests of nursng faculty. We also emphasize the potential for ongoing strategic program planning integrating components from other nursing partnerships in the Southeast Asian region. Conclusions/Implications for practice: If we are to continue meeting partnership goals, we must recognize that partnerships should evolve according to the goals of HueUMP nursing faculty and the context of nursing in Vietnam.

Teaching and motivating patients to achieve treatment goals

Mendoza, M. A. (2017). In Principles of Diabetes Mellitus (pp. 823-842). Springer International Publishing. 10.1007/978-3-319-18741-9_40
Diabetes is a complex, demanding, lifelong disease managed primarily by the individual and/or the family. The key to successful diabetes care is an approach that supports the patients' efforts to modify behavior in a systematic way. The management of this chronic disease is to provide the individual with knowledge, psychomotor skills, and effective psychological coping and most importantly continued motivation to facilitate lifestyle modifications. The process of adult learning is not an exact science. It is highly individualized. This chapter addresses practical aspects in diabetes self-management education. It discusses how to evaluate the readiness of the individual to enter the learning process. It describes strategies on how to motivate adults to learn diabetes self-management. The chapter also provides practical recommendations on how a physician can facilitate adult learning in a clinical setting. It addresses the issue of literacy and adherence to the self-management regimen. It also describes an innovative strategy to assist patients in goal setting and action planning. At the end of the chapter is a sampling of resources for patient education.

Behavioral and educational approaches to diabetes self-management

Mendoza, M. A., Welbeck, M., & Parikh, G. (2010). In Principles of Diabetes Mellitus (pp. 659-675). Springer US. 10.1007/978-0-387-09841-8-40
Diabetes is a life-long disease managed primarily by the individual. The key to successful self-management of this chronic disease is to provide the individual with knowledge, psychomotor skills, and effective psychological coping to facilitate lifestyle modifications. The process of adult learning is not an exact science. It is highly individualized. Oftentimes, the clinician would find that strategies successful for one person might not be successful for others.

Effects of intensive glucose lowering in type 2 diabetes

Failed generating bibliography.
Background Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. Methods In this randomized study, 10,250 patients (mean age, 60.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 37% were women, and 7% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. Results At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 70 patients in the intensive-therapy group, as compared with 359 in the standard-therapy group (hazard ratio, 0.88; 92% confidence interval [CI], 0.76 to 1.04; P = 0.16). At the same time, 255 patients in the intensive-therapy group died, as compared with 203 patients in the standardtherapy group (hazard ratio, 1.22; 92% CI, 1.01 to 1.45; P = 0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001). Conclusions As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000600.).

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods

Failed generating bibliography.
Most patients with type 2 diabetes mellitus develop cardiovascular disease (CVD), with substantial loss of life expectancy. Nonfatal CVD contributes greatly to excess healthcare costs and decreased quality of life in patients with diabetes. The current epidemic of obesity has raised expectations that CVD associated with type 2 diabetes will become an even greater public health challenge. Despite the importance of this health problem, there is a lack of definitive data on the effects of the intensive control of glycemia and other CVD risk factors on CVD event rates in patients with type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is a randomized, multicenter, double 2 - 2 factorial design study involving 10,251 middle-aged and older participants with type 2 diabetes who are at high risk for CVD events because of existing CVD or additional risk factors. ACCORD is testing the effects of 3 medical treatment strategies to reduce CVD morbidity and mortality. All participants are in the glycemia trial, which is testing the hypothesis that a therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of <6.0% will reduce the rate of CVD events more than a strategy that targets an HbA1c level of 7.0%-7.9%. The lipid trial includes 5,518 of the participants, who receive either fenofibrate or placebo in a double-masked fashion to test the hypothesis of whether, in the context of good glycemic control, a therapeutic strategy that uses a fibrate to increase high-density lipoprotein cholesterol and lower triglyceride levels together with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) to lower low-density lipoprotein cholesterol will reduce the rate of CVD events compared with a strategy that uses a statin plus a placebo. The blood pressure trial includes the remaining 4,733 participants and tests the hypothesis that a therapeutic strategy that targets a systolic blood pressure of <120 mm Hg in the context of good glycemic control will reduce the rate of CVD events compared with a strategy that targets a systolic blood pressure of <140 mm Hg. The primary outcome measure for all 3 research questions is the first occurrence of a major CVD event, specifically nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Upon the expected completion of participant follow-up in 2009, the ACCORD trial should document for the first time the benefits and risks of intensive glucose control, intensive blood pressure control, and the combination of fibrate and statin drugs in managing blood lipids in high-risk patients with type 2 diabetes.

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction

Failed generating bibliography.
Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. We did a randomised, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tenecteplase plus weight-adjusted unfractionated heparin in patients with acute myocardial infarction. Methods: 6095 patients with acute myocardial infarction of less than 6 h were randomly assigned one of three regimens: full-dose tenecteplase and enoxaparin for a maximum of 7 days (enoxaparin group; n=2040), half-dose tenecteplase with weight-adjusted low-dose unfractionated heparin and a 12-h infusion of abciximab (abciximab group; n=2017), or full-dose tenecteplase with weight-adjusted unfractionated heparin for 48 h (unfractionated heparin group; n=2038). The primary endpoints were the composites of 30-day mortality, in-hospital reinfarction, or in-hospital refractory ischaemia (efficacy endpoint), and the above endpoint plus in-hospital intracranial haemorrhage or in-hospital major bleeding complications (efficacy plus safety endpoint). Analysis was by intention to treat. Findings: There were significantly fewer efficacy endpoints in the enoxaparin and abciximab groups than in the unfractionated heparin group: 233/2037 (11.4%) versus 315/2038 (15.4%; relative risk 0.74 [95% CI 0.63-0.87], p=0.0002) for enoxaparin, and 223/2017 (11.1%) versus 315/2038 (15.4%; 0.72 [0.61-0.84], p<0.0001) for abciximab. The same was true for the efficacy plus safety endpoint: 280/2037 (13.7%) versus 347/2036 (17.0%; 0.81 [0.70-0.93], p=0.0037) for enoxaparin, and 287/2016 (14.2%) versus 347/2036 (17.0%; 0.84 [0.72-0.96], p=0.01416) for abciximab. Interpretation: The tenecteplase plus enoxaparin or abciximab regimens studied here reduce the frequency of ischaemic complications of an acute myocardial infarction. In light of its ease of administration, tenecteplase plus enoxaparin seems to be an attractive alternative reperfusion regimen that warrants further study.